Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Profusa, Inc.

Ticker
PFSA
Sector
Industry
Report date
November 14, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments include progress toward CE Mark for the Lumee platform, Nasdaq compliance resolution, multiple reverse stock splits, and ongoing acquisition efforts for G3 Vision Labs.

Recent developments:
  • Profusa advanced its Lumee Tissue Oxygen platform toward CE Mark regulatory approval in Europe, supporting commercialization efforts [N2].
  • The company received Nasdaq confirmation of compliance after resolving prior compliance issues, though shares declined following the announcement [N3].
  • Profusa executed another reverse stock split in August 2026 as part of share consolidation efforts [N4].
  • The company entered an option agreement to acquire G3 Vision Labs Inc., a diagnostics and toxicology testing business, subject to financing and approvals [N6].
  • Profusa reported wider Q2 losses and progress toward the G3 Vision Labs option agreement, with stock price declines noted [N4].
  • Lumee platform purchase orders in Europe supported an uplift in fiscal 2026 sales guidance [N5].
  • Profusa launched the Lumee platform in January 2026, initiating first commercial revenue [N5].
  • Significant executive leadership changes occurred in July 2026, including appointment of a new CEO and President [N6].
  • Profusa launched a $100 million Bitcoin treasury strategy in 2025 to enhance shareholder value [N7].
  • The company’s stock experienced volatility related to multiple reverse stock splits and acquisition news throughout 2026 [N4][N6].
Overview

Profusa, Inc. develops and commercializes biosensing technology primarily through its Lumee Tissue Oxygen platform, which enables continuous monitoring of tissue oxygen levels for healthcare research and clinical applications. The company has initiated first commercial revenue from Lumee and is progressing toward CE Mark regulatory approval in Europe. Profusa is pursuing strategic growth through an option agreement to acquire G3 Vision Labs Inc., a diagnostics and toxicology testing business, which involves complex conditions and integration challenges. The company has experienced multiple reverse stock splits in 2026 to consolidate its share structure and has addressed Nasdaq compliance matters. Financially, Profusa reported a net loss and limited liquidity as of Q3 2026, with ongoing risks related to dilution from warrants and preferred stock, as well as leadership transitions.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Profusa, Inc. is a biosensing technology company focused on tissue oxygen monitoring through its Lumee platform, which has initiated first commercial revenue and is advancing regulatory approval in Europe. The company reported a net loss of $4.95 million for Q3 2026 with constrained liquidity, holding $375,000 in cash against $21.1 million in current liabilities. Profusa is pursuing an acquisition of G3 Vision Labs Inc., subject to multiple conditions and integration risks. The company has undergone multiple reverse stock splits and resolved Nasdaq compliance issues in 2026. Executive leadership changes and warrant issuances present additional operational and dilution risks.

Scenarios for PFSA

Bull case model:

Profusa's advancement of the Lumee Tissue Oxygen platform toward CE Mark and initial commercial revenue demonstrate tangible progress in commercializing its biosensing technology. The strategic option agreement to acquire G3 Vision Labs could diversify and expand its product offerings into diagnostics and toxicology testing. Resolution of Nasdaq compliance issues and leadership appointments may stabilize operations. The company's innovative technology and partnerships, such as with Mayo Clinic, support potential growth in healthcare monitoring applications.

Bear case model:

Profusa faces significant liquidity constraints with a current ratio of 0.02 and net losses, raising concerns about financial sustainability. The acquisition of G3 Vision Labs carries integration risks, potential dilution from convertible preferred stock, and requires substantial financing and approvals. Multiple reverse stock splits indicate share price challenges. Leadership changes may disrupt business continuity. Dilution risks from warrants and preferred stock could adversely affect shareholder value. Regulatory and market acceptance risks remain for the Lumee platform.

Moat:

Profusa's moat lies in its proprietary biosensing technology platform for tissue oxygen monitoring, which addresses a niche in healthcare research and clinical diagnostics. The Lumee platform's early commercial launch and regulatory progress in Europe provide initial market entry barriers. However, the company's limited operating history, ongoing losses, and reliance on successful regulatory approvals and strategic acquisitions constrain its competitive advantage. Integration risks from acquisitions and potential dilution from financing instruments also impact the sustainability of its moat.

Risks overview
Risks summary
Profusa's most significant risks include constrained liquidity, uncertainties and integration challenges related to the proposed acquisition of G3 Vision Labs, and dilution risks from financing instruments.
Risks details:

• Liquidity Risk: Profusa's cash and current assets are significantly lower than current liabilities as of September 30, 2026, resulting in very low liquidity ratios that may constrain operational flexibility.
• Acquisition and Integration Risk: The option agreement to acquire G3 Vision Labs is subject to multiple conditions and financing requirements. Integration challenges due to differing business focuses and potential disruption to ongoing operations pose material risks.
• Dilution Risk: Issuance of Series A Non-Voting Convertible Preferred Stock and warrants related to debt financing may cause substantial dilution to existing shareholders and affect capital raising ability.
• Regulatory and Commercialization Risk: The Lumee platform is advancing toward CE Mark approval but remains subject to regulatory uncertainties and market acceptance challenges.
• Leadership and Operational Risk: Recent significant changes in executive leadership may disrupt business operations and strategic execution.
• Cybersecurity Risk: Profusa maintains active governance and oversight of cybersecurity risks, but potential incidents could disrupt operations and expose the company to liabilities.

FINAL FORECAST FOR PFSA

Final take one line
Profusa, Inc. exhibits very high visibility with detailed disclosures on its biosensing technology commercialization, acquisition plans, financials, and risks.
Final take 12 to 24 month view

Business trends: Progress in commercializing the Lumee Tissue Oxygen platform with regulatory advancement and initial revenue; strategic acquisition efforts to diversify offerings.
Execution milestones: Advancing CE Mark approval, completing conditions for G3 Vision Labs acquisition, resolving Nasdaq compliance, and stabilizing leadership.
Key risks: Liquidity constraints, integration and financing risks related to acquisition, dilution from warrants and preferred stock, and operational disruption from leadership changes.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Profusa, Inc. develops biosensing technology focused on tissue oxygen monitoring, commercialized through its Lumee platform.
  • The Lumee Tissue Oxygen platform has initiated first commercial revenue and is advancing toward CE Mark regulatory approval in Europe.
  • Profusa has entered an option agreement to acquire G3 Vision Labs Inc., a diagnostics and toxicology testing company, subject to multiple conditions including financing and approvals.
  • The company has executed multiple reverse stock splits in 2026 to consolidate its share structure.
  • Profusa reported a net loss of $4.95 million for the quarter ended September 30, 2026, with basic and diluted EPS of -6.23 USD per share.
  • As of September 30, 2026, Profusa had cash and equivalents of $375,000 and current assets of $394,000 against current liabilities of $21.1 million, resulting in a current ratio of 0.02.
  • Profusa's board and management maintain active oversight of cybersecurity risks, with the Audit Committee responsible for governance and regular briefings from the CEO and CFO.
  • The company recently resolved Nasdaq compliance issues and received confirmation of compliance.
  • Profusa launched a $100 million Bitcoin treasury strategy in 2025 to enhance shareholder value.
  • The acquisition of G3 Vision Labs presents integration risks due to differences in business focus and potential dilution from Series A Preferred Stock convertible into common shares.
  • Profusa issued warrants in connection with debt financing that may cause dilution and affect capital raising.
  • Significant executive leadership changes occurred in mid-2026, including appointment of a new CEO and President, with potential operational disruption.
  • Profusa's liquidity position is constrained with very low current and cash ratios as of Q3 2026.
  • The company has received purchase orders for Lumee tissue oxygen monitors in Europe, supporting sales guidance for fiscal 2026.
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
  • Profusa's 10-K filing dated 2026-04-15 details cybersecurity governance, risk management, and absence of material legal proceedings [S1].
  • The 10-Q filing dated 2026-11-13 outlines risks related to the G3 Vision Labs acquisition, dilution from warrants and preferred stock, leadership changes, and liquidity constraints [S2].
Sources - SEC Filings
  • S1 | 2026-04-15 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-09-24 | www.nasdaq.com | Biotech Stocks On The Move - APUS, PFSA, GCTK, ARCT | https://www.nasdaq.com/articles/biotech-stocks-move-apus-pfsa-gctk-arct
  • N2 | 2026-09-24 | www.nasdaq.com | Profusa Advances Lumee Oxygen Platform Toward CE Mark | https://www.nasdaq.com/articles/profusa-advances-lumee-oxygen-platform-toward-ce-mark
  • N3 | 2026-09-15 | www.nasdaq.com | Profusa Receives Nasdaq Confirmation Of Compliance ;Shares Slide | https://www.nasdaq.com/articles/profusa-receives-nasdaq-confirmation-compliance-shares-slide
  • N4 | 2026-08-18 | www.nasdaq.com | After-Hours Gainers: PFSA Executes Another Reverse Split, IVF Jumps On Q2 Results, AMLX Faces D-Day | https://www.nasdaq.com/articles/after-hours-gainers-pfsa-executes-another-reverse-split-ivf-jumps-q2-results-amlx-faces-d
  • N5 | 2026-08-07 | www.nasdaq.com | Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data | https://www.nasdaq.com/articles/weekly-buzz-mrna-nvs-sny-gain-approvals-ebs-lsta-cut-jobs-tars-bivi-drive-deals-data
  • N6 | 2026-07-27 | www.nasdaq.com | PFSA Stock Falls 19% Amid Diagnostics Acquisition News | https://www.nasdaq.com/articles/pfsa-stock-falls-19-amid-diagnostics-acquisition-news
  • N7 | 2026-07-21 | www.nasdaq.com | Top Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watch | https://www.nasdaq.com/articles/top-biotech-gainers-zybt-skyrockets-advb-drops-planned-offering-stim-gets-new-cfo-rdgt
  • N8 | 2026-04-10 | www.nasdaq.com | Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO | https://www.nasdaq.com/articles/weekly-buzz-mgnx-resumes-linnet-gsk-wins-china-nod-fda-okays-waters-nbix-snaps-slno
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine